Glen Harbor Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Glen Harbor Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$165K	Buy	2,744 +224	+9%	+$16.6K	﹤0.01%	1071
2019 Q2	$213K	Hold	2,520	–	–	﹤0.01%	999
2019 Q1	$241K	Hold	2,520	–	–	0.01%	931
2018 Q4	$178K	Hold	2,520	–	–	﹤0.01%	976
2018 Q3	$215K	Buy	2,520 +784	+45%	+$78.5K	﹤0.01%	1020
2018 Q2	$201K	Hold	1,736	–	–	﹤0.01%	972
2018 Q1	$140K	Buy	+1,736	New	+$134K	﹤0.01%	1077
2017 Q1	–	Sell	-560	Closed	-$19K	–	1277
2016 Q4	$19K	Buy	+560	New	+$16.1K	﹤0.01%	1204

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Glen Harbor Capital Management's ENTA Position: Q3 2019 in Review

Glen Harbor Capital Management increased its Enanta Pharmaceuticals (ENTA) stake by 8.9% in Q3 2019, buying an estimated $16.6K and bringing the position to 2,744 shares worth $165K. The position accounts for ﹤0.01% of the portfolio, ranked #1071.

Glen Harbor Capital Management first reported a position in ENTA in Q4 2016 and has held it in 8 quarters since. The position peaked at $241K in Q1 2019. 176 funds tracked by Wall St. Rank hold ENTA as of Q3 2019.

Glen Harbor Capital Management held 2,744 shares of Enanta Pharmaceuticals worth $165K as of Q3 2019.
Glen Harbor Capital Management bought 224 Enanta Pharmaceuticals shares in Q3 2019, an estimated $16.6K.
Enanta Pharmaceuticals made up ﹤0.01% of Glen Harbor Capital Management's portfolio in Q3 2019, its #1071 holding.
Glen Harbor Capital Management first reported a position in Enanta Pharmaceuticals in Q4 2016 and has held it in 8 quarters since.
Glen Harbor Capital Management's Enanta Pharmaceuticals position peaked at $241K in Q1 2019.
176 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2019.

Based on Glen Harbor Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.